Sort
21,281 grants matching “influenza”
RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$1,400,000Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2023 · IP
Center for Investigating Viral Immunity and Antagonism
$1,399,999Thomas M Moran · Icahn School Of Medicine At Mount Sinai · U19 · FY2009 · AI
Development of a Universal Influenza Vaccine
$1,398,670Frank R. Jones · Etubics Corporation · R01 · FY2014 · AI
CNH: Coupled Natural-Human Systems and Emerging Infectious Diseases
$1,398,380Jefferson M Fox · Center For Cultural&Tech Interchg East&West · · FY2009 · BIO
Clinical Studies of Vaccines for Pandemic Influenza
$1,397,944Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS
$1,397,389Peter Palese · Icahn School Of Medicine At Mount Sinai · U01 · FY2008 · AI
Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
$1,397,144Elisabetta Patorno · Brigham And Women'S Hospital · U01 · FY2022 · FD
Alphavirus replicon vectors as dose-sparing adjuvants for Influenza vaccines.
$1,396,158Robert Olmsted · Alphavax Human Vaccines, Inc. · U01 · FY2009 · AI
Development of drugs that target the M2 proton channel from the influenza A Virus
$1,396,058William F Degrado · University Of Pennsylvania · U01 · FY2011 · AI
Membrane Remodeling in Viral Infection and Viral Assembly
$1,395,355Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD
NIRT: Combinatorial Engineering of Nanomachines: Building Novel Membrane Proteins via De Novo Design and Directed Evolution
$1,395,000Eric Boder · University Of Pennsylvania · · FY2002 · ENG
Germline targeting influenza immunogens
$1,394,075David Nemazee · Scripps Research Institute, The · R01 · FY2020 · AI
Germline targeting influenza immunogens
$1,394,075David Nemazee · Scripps Research Institute, The · R01 · FY2019 · AI
Germline targeting influenza immunogens
$1,394,075David Nemazee · Scripps Research Institute, The · R01 · FY2021 · AI
Germline targeting influenza immunogens
$1,394,075David Nemazee · Scripps Research Institute, The · R01 · FY2018 · AI
Development of a novel adjuvant for vaccine sparing
$1,393,822Sara Lustigman · New York Blood Center · R01 · FY2013 · AI
Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination
$1,393,521Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2017 · AI
Immunostimulatory Patch To Enhance Biodefense Vaccines
$1,392,960Larry R Ellingsworth · Iomai Corporation · U01 · FY2006 · AI
Small-molecule adjuvants testing pipeline (Influenza)
$1,392,087Ofer Levy · Boston Children'S Hospital · N01 · FY2023 · AI
Drivers of individual variation in influenza vaccine response and protection from infection
$1,391,997Sarah Cobey · University Of Chicago · R01 · FY2025 · AI
Comprehensive multimodal analysis of patients with neuroimmunological diseases
$1,388,137Bibiana Bielekova · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza
$1,387,684Aaron Esser-Kahn · University Of Chicago · N01 · FY2022 · AI
Non-Viral Pandemic Influenza Vaccine Development
$1,387,125Gary Fujii · Molecular Express, Inc. · U01 · FY2007 · AI
CIPRA-SA: Safeguard the household: comprehensive AIDS research: Extension
$1,386,629James Alasdair McIntyre · Wits Health Consortium (Pty), Ltd · U19 · FY2010 · AI
Emerging respiratory viruses - pathogenesis and countermeasures
$1,385,462Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI